Characteristics of anemia in heart failure: iron metabolism, erythropoietic activity and markers of inflammation
https://doi.org/10.15829/1728-8800-2023-3332
Abstract
Aim. To determine the characteristics of erythrocyte parameters, iron metabolism, erythropoiesis, inflammation markers in patients with heart failure (CHF) and anemia.
Material and methods. The study included 68 patients with HF to describe the characteristics of anemia (general group). Patients of the general group were divided into 3 subgroups depending on the serum ferritin (SF) and transferrin saturation (TS).
Results. Anemia in HF is not always associated with iron deficiency (ID), characterized by inadequate production of erythropoietin, increased levels of C-reactive protein and hepcidin. From the general group of patients, the following were distinguished: absolute ID (43%), functional ID (19%), and non-ID anemia (38%).
Conclusion. In the general group of patients with HF, anemia is normochromic, normocytic, characterized by high levels of C-reactive protein, hepcidin, and inadequate production of erythropoietin. Patients with absolute and functional ID do not differ in the main iron metabolism parameters and in general account for 62% (p=0,01). In these two subgroups, iron supplements should be prescribed at further stages.
About the Authors
A. A. Gurkina
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Moscow
N. I. Stuklov
Peoples’ Friendship University of Russia; National Medical Research Center of Radiology
Russian Federation
Russian Federation
Moscow
N. D. Kisly
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Moscow
R. R. Gimadiev
Peoples’ Friendship University of Russia; Eurotest, OOO
Russian Federation
Russian Federation
Moscow
M. S. Kovalchuk
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Moscow
References
1. Rizzo C, Carbonara R, Ruggieri R, et al. Iron deficiency: a new target for patients with heart failure. Front Cardiovasc Med. 2021;908. doi:10.3389/fcvm.2021.709872.
2. Zahidova KK. Selection of Optimal Therapy at Correction of the Anemic Syndrome in Patients with Chronic Heart Failure. Kardiologiia. 2018;1:25-31. (In Russ.) doi:10.18087/cardio.2018.1.10076.
3. Tkachenko EI, Borovkova NY, Buyanova MV. Anemia in chronic heart failure: a look at the pathogenesis and ways of correction. Doctor. Ru. 2019;2(157):31-6. (In Russ.) doi:10.31550/1727-2378-2019-157-2-31-36.
4. Anand IS, Gupta P. (Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation. 2018;138(1):80-98. doi:10.1161/CIRCULATIONAHA.118.030099.
5. Vatutin, NT, Taradin GG, Kanisheva IV, et al. Anaemia and iron deficiency in chronic heart failure patients. Kardiologiia. 2019;59(4S):4-20. (In Russ.) doi:10.18087/cardio.2638.
6. Silverberg DS, Dov W, Schwartz D. Is correction of iron deficiency a new addition to the treatment of the heart failure? Int J Mol Sci. 2015;16(6):14056-74. doi:10.3390/ijms160614056.
7. Ezekowitz JA, O’Meara E, McDonald MA, et al. 2017 Compreh ensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. Can J Cardiol. 2017;33(11):1342-433. doi:10.1016/j.cjca.2017.08.022.
8. Stuklov NI. Iron deficiency and anemia in patients with chronic heart failure. Rational Pharmacotherapy in Cardiology. 2017;13(5):651-60. (In Russ.) doi:10.20996/1819-6446-2017-13-5-651-660.
9. Rukavitsyn OA. Anemia. 2nd ed., revised. and additional. M.: GEOTAR-Media, 2016. 250 р. (In Russ.) ISBN:978-5-9704-4475-7.
10. Pozzo J, Fournier P, Delmas C, et al. Absolute iron deficiency without anaemia in patients with chronic systolic heart failure is associated with poorer functional capacity. Arch Cardiovasc Dis. 2017;110(2):99-105. doi:10.1016/j.acvd.2016.06.003.
11. Wong CC, Ng AC, Kritharides L, et al. Iron deficiency in heart failure: looking beyond anaemia. Heart, Lung and Circulation. 2016;25(3):209-16. doi:10.1016/j.hlc.2015.06.827.
12. Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet (London, England). 2020;396(10266):1895-904. doi:10.1016/s0140-6736(20)32339-4.
13. Zykov MV, Kashtalap VV, Bykova IS, et al. Comorbidity in acute heart failure complicating myocardial infarction. Russian Journal of Cardiology. 2020;25(7):3427. (In Russ.) doi:10.15829/1560-4071-2020-3427.
14. Akimova AV, Nevskaya AV, Milashchenko AI, et al. Features of anemia of chronic diseases in a therapeutic hospital. Bulletin of the Ural medical academic science. 2018;15(1):5-11. (In Russ.) doi:10.22138/2500-0918-2018-15-1-5-11.
15. Solomakhina NI, Nakhodnova ES, Gitel EP, et al. Hepcidin and its relationship with inflammation in old and older patients with anemia of chronic disease associated with CHF. Kardiologiia. 2018;58(S2):4-11. (In Russ.) doi:10.18087/cardio.2457.
16. Anker SD, Kirwan BA, Dirk JV, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018;20(1):125-33. doi:10.1002/ejhf.823.
17. McDonagh T, Damy T, Doehner W, et al. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. Eur J Heart Fail. 2018;20(12):1664-72. doi:10.1002/ejhf.1305.
18. Ageev, FT, Arutyunov TG. Chronic heart failure. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) doi:10.15829/1560-4071-2020-4083.
19. Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136(15):1374-83. doi:10.1161/CIRCULATIONAHA.117.027497.
20. Zykov MV, Kashtalap VV, Bykova IS. Association of multimorbidity with the risk of developing cardiovascular complications in patients with acute coronary syndrome. Cardiology Bulletin. 2018;2:59-65. (In Russ.) doi:10.17116/Cardiobulletin201813259.
21. Lewis GD, Semigran MJ, Givertz MM, et al. Oral iron therapy for heart failure with reduced ejection fraction: design and rationale for oral iron repletion effects on oxygen uptake in heart failure. Circ Heart Fail. 2016;9(5):e000345. doi:10.1161/CIRCHEARTFAILURE.115.000345.
22. Shilov AM, Melnik MV, Retivykh ON, Kim IR. Correction of iron deficiency anemia in chronic heart failure. Russkij Medicinskij Zhurnal. 2005;19:1254-7. (In Russ.)
23. Larina VN, Bart BY, Larin VG. Clinical significance of anemic syndrome in patients with chronic heart failure. Rational Pharmacotherapy in Cardiology. 2010;6(3):311-7. (In Russ.) doi:10.20996/1819-6446-2010-6-3-311-317.
24. Demihov VG, Lebedev VV, Demihova EV, et al. Iron deficiency syndromes as the basis of a personalized approach to the treatment of anemia in pediatric practice. Pediatrics. Consilium Medicum. 2020;2:80-4. (In Russ.) doi:10.26442/26586630.2020.2.200242.
Supplementary files
What is already known about the subject?
- Erythrocyte parameters in anemia, erythropoietic activity, markers of inflammation and regulation of iron metabolism in heart failure (CHF) have been studied in detail.
What might this study add?
- The obtained results prove that the majority of anemias in HF meet the criteria for anemia of inflammation in combination with iron deficiency. In this category of patients, ferritin level and transferrin saturation before the study is the most important marker of effectiveness of anemia treatment in HF, which is important for general practitioners.
Review
For citations:
Gurkina A.A., Stuklov N.I., Kisly N.D., Gimadiev R.R., Kovalchuk M.S. Characteristics of anemia in heart failure: iron metabolism, erythropoietic activity and markers of inflammation. Cardiovascular Therapy and Prevention. 2023;22(1):3332. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3332
Views:
2720
Email this article 
